CD74 and metabolic dysfunction-associated steatohepatitis: Therefore, CD74 could be a potential novel target to disrupt NASH progression and development of fibrosis, by using an anti-CD74 antibody such as milatuzumab (also known as hLL1), for example (40, 41).